

Gustav Gaudernack

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7026905/publications.pdf>

Version: 2024-02-01

94
papers

5,395
citations

81900

39
h-index

88630

70
g-index

95
all docs

95
docs citations

95
times ranked

6070
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic vaccines for cancer: an overview of clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 509-524.	27.6	636
2	HLA class I and II typing using cells positively selected from blood by immunomagnetic isolation – a fast and reliable technique. <i>Tissue Antigens</i> , 1986, 28, 301-312.	1.0	267
3	Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. <i>International Journal of Cancer</i> , 2001, 92, 441-450.	5.1	261
4	Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1499-1509.	4.2	236
5	Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1553-1564.	4.2	220
6	Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. <i>International Journal of Cancer</i> , 2011, 128, 1120-1128.	5.1	156
7	Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors. <i>International Journal of Cancer</i> , 1997, 74, 664-669.	5.1	153
8	Genomic instability, DNA methylation, and natural selection in colorectal carcinogenesis. <i>Seminars in Cancer Biology</i> , 1999, 9, 245-254.	9.6	150
9	Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial. <i>Clinical Cancer Research</i> , 2011, 17, 6847-6857.	7.0	149
10	Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12VAL) peptide vaccination of a patient, recognize 12VAL-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. , 1997, 72, 784-790.		147
11	Isolation of pure functionally active CD8+ T cells positive selection with monoclonal antibodies directly conjugated to monosized magnetic microspheres. <i>Journal of Immunological Methods</i> , 1986, 90, 179-187.	1.4	140
12	Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma. <i>International Journal of Cancer</i> , 2014, 134, 102-113.	5.1	129
13	mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). <i>Journal of Immunological Methods</i> , 2002, 259, 191-203.	1.4	127
14	Identification and Characterization of Cells with Cancer Stem Cell Properties in Human Primary Lung Cancer Cell Lines. <i>PLoS ONE</i> , 2013, 8, e57020.	2.5	109
15	Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients. <i>Clinical Cancer Research</i> , 2011, 17, 4568-4580.	7.0	105
16	Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study. , 1996, 65, 450-453.		97
17	Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. <i>Onc Immunology</i> , 2012, 1, 670-686.	4.6	95
18	hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 809-818.	4.2	85

#	ARTICLE	IF	CITATIONS
19	p21 <i>ras</i> peptide-specific T cell responses in a patient with colorectal cancer. CD4 ⁺ and CD8 ⁺ T cells recognize a peptide corresponding to a common mutation (13Gly → Asp). <i>International Journal of Cancer</i> , 1994, 56, 40-45.	5.1	79
20	Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention. <i>Toxicology Reports</i> , 2020, 7, 768-771.	3.3	79
21	Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1432-1442.	4.2	78
22	A TCR-based Chimeric Antigen Receptor. <i>Scientific Reports</i> , 2017, 7, 10713.	3.3	76
23	Carcinogenesis and Natural Selection: A New Perspective to the Genetics and Epigenetics of Colorectal Cancer. <i>Advances in Cancer Research</i> , 1999, 76, 187-212.	5.0	74
24	Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 891-901.	4.2	71
25	A TGFβ ² RII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8 + T cells. <i>Cancer Immunology, Immunotherapy</i> , 2001, 50, 469-476.	4.2	67
26	T-cell responses against products of oncogenes: Generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides. <i>Human Immunology</i> , 1992, 33, 266-274.	2.4	63
27	Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency. <i>Cancer Research</i> , 2016, 76, 4347-4358.	0.9	63
28	Overlapping epitopes encompassing a point mutation (12 Gly → Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells. <i>European Journal of Immunology</i> , 1993, 23, 2687-2691.	2.9	62
29	Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln → Leu61). <i>International Immunology</i> , 1992, 4, 1331-1337.	4.0	60
30	Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 431-438.	4.2	60
31	T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 659-675.	4.2	60
32	Transiently redirected T cells for adoptive transfer. <i>Cytotherapy</i> , 2011, 13, 629-640.	0.7	58
33	Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination. <i>Cancer Gene Therapy</i> , 2005, 12, 579-591.	4.6	57
34	T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces <i>in vivo</i> tumor growth. <i>OncImmunity</i> , 2017, 6, e1302631.	4.6	57
35	NK cells specifically TCR-dressed to kill cancer cells. <i>EBioMedicine</i> , 2019, 40, 106-117.	6.1	56
36	T cell clones specific for p21 ras-derived peptides: Characterization of their fine specificity and HLA restriction. <i>European Journal of Immunology</i> , 1993, 23, 754-760.	2.9	54

#	ARTICLE	IF	CITATIONS
37	Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1609-1626.	4.2	44
38	Identification of Cancer Stem-like Side Population Cells in Ovarian Cancer Cell Line OVCAR-3. <i>Ultrastructural Pathology</i> , 2009, 33, 175-181.	0.9	42
39	Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1553-1564.	4.2	42
40	Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1609-1621.	4.2	42
41	Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy. <i>International Journal of Cancer</i> , 2002, 99, 100-105.	5.1	40
42	Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells. <i>Oncolimmunology</i> , 2016, 5, e1232237.	4.6	38
43	A K-ras 13GLY $\hat{\text{a}}$ t ⁺ ASP mutation is recognized by HLA-DQ7 restricted T cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harbouring this mutation?. <i>International Journal of Cancer</i> , 1994, 58, 506-511.	5.1	36
44	Differences in the distribution of CD34 epitopes on normal haemopoietic progenitor cells and leukaemic blast cells. <i>British Journal of Haematology</i> , 1996, 94, 597-605.	2.5	29
45	Intracellular events associated with inhibition of B cell activation by monoclonal antibodies to HLA class II antigens. <i>European Journal of Immunology</i> , 1989, 19, 1221-1225.	2.9	28
46	T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA. <i>European Journal of Immunology</i> , 1994, 24, 410-414.	2.9	28
47	Resolving the evolutionary paradox of genetic instability: a cost-benefit analysis of DNA repair in changing environments. <i>FEBS Letters</i> , 2004, 563, 7-12.	2.8	27
48	HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes. <i>Journal of Molecular Medicine</i> , 2003, 81, 43-50.	3.9	26
49	Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma. <i>Cancer Gene Therapy</i> , 2005, 12, 699-707.	4.6	26
50	Positive selection of activated T cells of the T8 (CD8) sub $\hat{\text{a}}$ type by immunomagnetic separation. <i>Tissue Antigens</i> , 1986, 28, 46-52.	1.0	26
51	T lymphocyte clones recognizing an HLA-DQw3.2-associated epitope involving residue 57 on the DQ $\hat{\text{I}}$ ² chain. <i>Human Immunology</i> , 1988, 22, 235-246.	2.4	25
52	Reliable isolation of human immunodeficiency virus from cultures of naturally infected CD4+ T cells. <i>Journal of Virological Methods</i> , 1989, 25, 293-300.	2.1	25
53	Characterization of an HLA-DQ2-specific monoclonal antibody. <i>Human Immunology</i> , 1995, 42, 319-327.	2.4	24
54	Mutation Detection in KRAS Exon 1 by Constant Denaturant Capillary Electrophoresis in 96 Parallel Capillaries. <i>Analytical Biochemistry</i> , 2002, 304, 200-205.	2.4	24

#	ARTICLE	IF	CITATIONS
55	Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1934-1944.	1.3	22
56	Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 572172.	4.8	21
57	Antigen-specific T cell clones restricted by DR, DRw53 (MT), or DP (SB) class II HLA molecules. Inhibition studies with monoclonal HLA-specific antibodies. <i>Human Immunology</i> , 1984, 11, 207-217.	2.4	20
58	Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity. <i>Oncolmmunology</i> , 2019, 8, 1558663.	4.6	20
59	Identification of Cancer Stem-like Side Population Cells in Ovarian Cancer Cell Line OVCAR-3. <i>Ultrastructural Pathology</i> , 2009, 33, 175-181.	0.9	20
60	T cells recognizing an HLA-DQ $\hat{\pm}$ heterodimer encoded in Cis by the DR4DQw4 haplotype and in Trans by DR4DQw8/DRw8DQw4 heterozygous cells. <i>Human Immunology</i> , 1991, 30, 226-232.	2.4	19
61	Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab. <i>Leukemia and Lymphoma</i> , 2013, 54, 2205-2214.	1.3	18
62	Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential. <i>Frontiers in Immunology</i> , 2021, 12, 682492.	4.8	18
63	Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial. <i>Frontiers in Immunology</i> , 2021, 12, 663865.	4.8	17
64	T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy. <i>Oncolmmunology</i> , 2016, 5, e1249090.	4.6	16
65	Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy. <i>Molecular Therapy</i> , 2021, 29, 1199-1213.	8.2	16
66	Prospects for vaccine therapy for pancreatic cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2006, 20, 299-314.	2.4	15
67	CDw78 $\hat{\epsilon}$ a determinant on a major histocompatibility complex class II subpopulation that can be induced to associate with the cytoskeleton. <i>European Journal of Immunology</i> , 1997, 27, 3206-3213.	2.9	12
68	Mutation Analysis of <i>TP53</i> Exons 5–8 by Automated Constant Denaturant Capillary Electrophoresis. <i>Tumor Biology</i> , 2001, 22, 323-327.	1.8	12
69	Identification of prostate cancer antigens by automated high-throughput filter immunoscreening. <i>Journal of Immunological Methods</i> , 2008, 330, 12-23.	1.4	12
70	The PhastSystem equipment used for crossed immunoelectrophoresis combined with immunoblotting of coprecipitated monoclonal antibodies as studied with platelet membrane receptor proteins. <i>Electrophoresis</i> , 1989, 10, 752-758.	2.4	11
71	Generation and characterization of GP-100 peptide-specific NK-T cell clones. , 1998, 75, 794-803.		11
72	Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1235-1243.	4.2	11

#	ARTICLE	IF	CITATIONS
73	Isolation of functionally active T cell receptor $\hat{\beta}$ -bearing lymphocytes from human peripheral blood. <i>Journal of Immunological Methods</i> , 1989, 118, 251-255.	1.4	10
74	Antigen-presenting function of human peritoneum mesothelial cells isolated from a pancreatic carcinoma patient after mutant Ras peptide vaccination. <i>Cancer Immunology, Immunotherapy</i> , 1997, 43, 262-268.	4.2	10
75	Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors. <i>Oncolmmunology</i> , 2021, 10, 1936757.	4.6	10
76	A simple and sensitive bioassay for the detection of IL-2 activity. <i>Journal of Immunological Methods</i> , 1988, 114, 95-99.	1.4	7
77	EBV infection renders B cells resistant to growth inhibition via adenylyl cyclase. <i>Cellular Signalling</i> , 2008, 20, 1169-1178.	3.6	7
78	Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination. <i>Oncolmmunology</i> , 2019, 8, e1565236.	4.6	7
79	Lymphoid cell distribution as prognostic factor in carcinoma of the uterine cervix. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 1992, 71, 135-139.	2.8	6
80	Analysis of the autoantibody repertoire in Burkitt's lymphoma patients: frequent response against the transcription factor ATF-2. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 1119-1126.	4.2	6
81	Awareness and understanding of cancer immunotherapy in Europe. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1828-1835.	3.3	6
82	Heterogeneity of T cells specific for a particular peptide/HLA-DQ complex. <i>Human Immunology</i> , 1994, 39, 61-68.	2.4	5
83	PD-1 blocker to rescue NK γ activity from PD-1-mediated tumor escape mechanisms. <i>FASEB Journal</i> , 2021, 35, e21750.	0.5	5
84	Effect of vaccination with mutant KRAS peptides on rat colon carcinogenesis induced by azoxymethane. <i>Anticancer Research</i> , 2002, 22, 171-5.	1.1	5
85	Rapid identification of human B-lymphocytes and monocytes with rhodamine-labeled <i>Brucella melitensis</i> . <i>Journal of Immunological Methods</i> , 1981, 43, 251-259.	1.4	4
86	Suppressive Effect of Monocytes in Vitro in Patients with Carcinoma of the Uterine Cervix. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 1986, 65, 619-624.	2.8	3
87	T cell responses against mutant ras: a basis for novel cancer vaccines. <i>Immunotechnology: an International Journal of Immunological Engineering</i> , 1996, 2, 3-9.	2.4	2
88	Studies on PIVKA-X. <i>Thrombosis and Haemostasis</i> , 1975, 34, 455-464.	3.4	1
89	T Cell Responses in Patients Vaccinated with Telomerase (hTERT)-mRNA Transfected Dendritic Cells.. <i>Blood</i> , 2009, 114, 373-373.	1.4	1
90	HLA restriction fine specificity and T cell receptor usage of T cells recognizing DQ7. <i>Tissue Antigens</i> , 1994, 43, 266-270.	1.0	0

#	ARTICLE	IF	CITATIONS
91	Efficient Generation of Tumor-Specific, Cytotoxic T Cells by Genetic Transfer of allo-MHC.. Blood, 2007, 110, 2755-2755.	1.4	0
92	RNA Based Cancer Vaccines - Clinical Trials in Patients with Prostate Cancer and Malignant Melanoma.. Blood, 2007, 110, 1805-1805.	1.4	0
93	A Novel Cancer Vaccine Strategy In Previously Untreated Patients with Stage III/IV Follicular Lymphoma Generates Tumor-Reactive T Cells and Clinical Response. Blood, 2010, 116, 1804-1804.	1.4	0
94	Clinical and Immunological Response Following hTERT/Survivin mRNA-Loaded Dendritic Cell Vaccination Combined With Ex-Vivo Expanded T Cell Transfer In Melanoma Patients. Blood, 2013, 122, 4487-4487.	1.4	0